>

Marcus Wallenberg - Astrazeneca PLC Non-Executive Director

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 25px;;'>AS</div>
AZN -- USA Stock  

Earning Report: 24th of April 2020  

  Director
Mr. Marcus Wallenberg is NonExecutive Director of AstraZeneca PLC. He has international business experience across various industry sectors, including the pharmaceutical industry from his directorship with Astra prior to 1999. Marcus is Chairman of Skandinaviska Enskilda Banken AB, Saab AB and FAM AB. He is a member of the boards of Investor AB, Temasek Holdings Limited, and the Knut and Alice Wallenberg Foundation.
Age: 63  Director Since 1999      
(44) 1223 352 858  www.astrazeneca.com

Management Efficiency

The company has Return on Asset of 0.03 % which means that on every $100 spent on asset it made $0.03 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.18 % implying that it generated $0.18 on every 100 dollars invested.
The company has 20.43 B in debt with debt to equity (D/E) ratio of 139.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Astrazeneca PLC has Current Ratio of 0.84 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Harish ManwaniGilead Sciences
2018
Peter WendellMerck Company
2003
Mary CoeMerck Company
2019
Don CornwellPfizer
1997
Ronald WilliamsJohnson Johnson
2011
Jackson TaiEli Lilly And Company
2013
Vivienne CoxGlaxoSmithKline PLC
2017
Franklyn PrendergastEli Lilly And Company
1995
Erik FyrwaldEli Lilly And Company
2005
Richard WhitleyGilead Sciences
2008
John CoganGilead Sciences
2013
Dinesh PaliwalBristol Myers Squibb Company
2013
Karen WalkerEli Lilly And Company
2018
Ellen MarramEli Lilly And Company
2013
Jamere JacksonEli Lilly And Company
2016
Craig ThompsonMerck Company
2008
Deryck MaughanGlaxoSmithKline PLC
2013
James BloemAllergan Plc
2013
Christopher CoughlinAllergan Plc
2016
Fred WeissAllergan Plc
2013
Paul RothmanMerck Company
2015

Company Summary

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca PLC operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 70600 people.Astrazeneca PLC (AZN) is traded on BATS Exchange in USA. It is located in 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom and employs 70,600 people. Astrazeneca PLC is listed under Pharmaceutical Products category by Fama And French industry classification.

Astrazeneca PLC Leadership Team

Marc Dunoyer, Chief Financial Officer, Executive DirectorView
Sherilyn McCoy, Non-Executive Independent DirectorView
Genevieve Berger, Non-Executive Independent DirectorView
Luke Miels, Executive Vice-President GPPSView
Sean Bohen, Chief Medical Officer, Executive Vice President - Global Medicines DevelopmentView
Paul Hudson, Executive Vice President North AmericaView
Nazneen Rahman, Non-Executive Independent DirectorView
Jose Baselga, Executive Vice President - Research & Development OncologyView
JeanPhilippe Courtois, Non-Executive Independent DirectorView
Thomas Larsen, IR Contact OfficerView
Katarina Ageborg, Executive Vice President - Sustainability, Chief Compliance OfficerView
Tony Mok, Non-Executive Independent DirectorView
Mark Mallon, Executive Vice President InternationalView
Fiona Cicconi, Executive Vice President - Human ResourcesView
Deborah DiSanzo, Non-Executive Independent DirectorView
Shriti Vadera, Non-Executive Independent DirectorView
Leif Johansson, Non-Executive Independent Chairman of the BoardView
Leon Wang, Executive Vice President - International and China PresidentView
Ann Cairns, Non-Executive DirectorView
Adrian Kemp, Company SecretaryView
Cornelia Bargmann, Non-Executive DirectorView
Tim JacksonSmith, Non-Executive DirectorView
Michel Demare, Non-Executive Independent DirectorView
Graham Chipchase, Senior Non-Executive Independent DirectorView
David Smith, Executive VP of Operations and Information ServicesView
Pascal Soriot, CEO, Executive Director and Member of Disclosure CommitteeView
Pam Cheng, Executive Vice-President of Operations and Information TechnologyView
Baroness Vadera, Non-Executive Independent DirectorView
Philip Broadley, Non-Executive Independent DirectorView
Narayan Seshadri, Independent DirectorView
Jeffrey Pott, General CounselView
Ruud Dobber, Executive Vice President, BioPharmaceuticals BusinessView
David Fredrickson, Executive Vice-President Global Head Oncology Business UnitView
Bahija Jallal, Executive Vice President MedImmuneView
Rudolph Markham, Non-Executive Independent DirectorView
Menelas Pangalos, Executive Vice President - Research & Development BioPharmaceuticalsView
Weiying Wang, Non-Executive DirectorView
Bruce Burlington, Non-Executive Independent DirectorView
Marcus Wallenberg, Non-Executive DirectorView
Iskra Reic, Executive Vice President - Europe and CanadaView

Stock Performance Indicators

Did you try this?

Run Correlation Analysis Now

   

Correlation Analysis

Reduce portfolio risk simply by holding instruments which are not perfectly correlated
All  Next Launch Module

Astrazeneca PLC Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Astrazeneca PLC and Novartis AG. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Please also try Financial Widgets module to easily integrated macroaxis content with over 30 different plug-and-play financial widgets.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page